New digital health technologies could lead to better care for Parkinson's disease

New digital health technologies could lead to better care for Parkinson’s disease
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease. This perspective paper is co-authored by the academic leader of the largest funded project for digital technologies in Europe, Professor Lynn Rochester, University of Newcastle; European Medicines Agency (EMA) scientific leader, Dr. Maria Tome; young investigator and Ph.D. candidate Reham Badawy; physician and Parkinson's patient, Dr. Soania Mathur; and Dr. Diane Stephenson, Executive Director of the Critical Path for Parkinson's (CPP) Consortium.

Related Keywords

Diane Stephenson ,Soania Mathur ,Lynn Rochester ,Maria Tome ,Reham Badawy ,Emily Henderson ,Critical Path Institute ,European Medicines Agency ,Drug Administration ,Digital Drug Development Tool ,University Of Newcastle ,Progression Biomarkers ,Novel Endpoints ,Clinical Trials ,Multistakeholder Perspective ,Professor Lynn Rochester ,Executive Director ,Critical Path ,Drug Development Tool ,Bas Bloem ,டயான் ஸ்டீபன்சன் ,லின் ரோசெஸ்டர் ,மரியா எனக்கு ,எமிலி ஹென்டர்சன் ,முக்கியமான பாதை நிறுவனம் ,பல்கலைக்கழகம் ஆஃப் நியூகேஸில் ,மருத்துவ சோதனைகள் ,நிர்வாகி இயக்குனர் ,முக்கியமான பாதை ,அடிப்படை பூக்கும் ,